98 related articles for article (PubMed ID: 3934802)
1. Inactivation of viruses in labile blood derivatives. II. Physical methods.
Horowitz B; Wiebe ME; Lippin A; Vandersande J; Stryker MH
Transfusion; 1985; 25(6):523-7. PubMed ID: 3934802
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations.
Horowitz B; Wiebe ME; Lippin A; Stryker MH
Transfusion; 1985; 25(6):516-22. PubMed ID: 3934801
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids.
Horowitz B; Piët MP; Prince AM; Edwards CA; Lippin A; Walakovits LA
Vox Sang; 1988; 54(1):14-20. PubMed ID: 2831669
[TBL] [Abstract][Full Text] [Related]
4. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
[TBL] [Abstract][Full Text] [Related]
5. Laboratory and preclinical evaluation of the virus safety of coagulation factor concentrates.
Horowitz B; Prince AM
Dev Biol Stand; 1987; 67():291-302. PubMed ID: 3609483
[TBL] [Abstract][Full Text] [Related]
6. Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy.
Savage M; Torres J; Franks L; Masecar B; Hotta J
Biologicals; 1998 Jun; 26(2):119-24. PubMed ID: 9811517
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of human T-cell lymphotropic virus, type III by heat, chemicals, and irradiation.
Quinnan GV; Wells MA; Wittek AE; Phelan MA; Mayner RE; Feinstone S; Purcell RH; Epstein JS
Transfusion; 1986; 26(5):481-3. PubMed ID: 3094204
[TBL] [Abstract][Full Text] [Related]
8. Effect of monosaccharides during severe dry heat treatment of coagulation factor VIII concentrates.
Knevelman A; de Wit HJ; Griffin B; Hart H; McIntosh RV
Vox Sang; 1994; 66(2):96-103. PubMed ID: 8184599
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors.
Hiemstra H; Tersmette M; Vos AH; Over J; van Berkel MP; de Bree H
Transfusion; 1991 Jan; 31(1):32-9. PubMed ID: 1898786
[TBL] [Abstract][Full Text] [Related]
10. Pasteurization of antihemophilic factor and model virus inactivation studies.
Ng PK; Dobkin MB
Thromb Res; 1985 Aug; 39(4):439-47. PubMed ID: 3931293
[TBL] [Abstract][Full Text] [Related]
11. Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants.
Chin S; Williams B; Gottlieb P; Margolis-Nunno H; Ben-Hur E; Hamman J; Jin R; Dubovi E; Horowitz B
Blood; 1995 Dec; 86(11):4331-6. PubMed ID: 7492794
[TBL] [Abstract][Full Text] [Related]
12. Characterization of F VIII concentrates produced by two methods incorporating double virus inactivation.
Branović K; Gebauer B; Trescec A; Benko B
Appl Biochem Biotechnol; 1998 Feb; 69(2):99-111. PubMed ID: 9513991
[TBL] [Abstract][Full Text] [Related]
13. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
Roberts PL; Dunkerley C; McAuley A; Winkelman L
Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
[TBL] [Abstract][Full Text] [Related]
14. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
15. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
Weiss HJ; Sussman II; Hoyer LW
J Clin Invest; 1977 Aug; 60(2):390-404. PubMed ID: 17621
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates.
Heldebrant CM; Gomperts ED; Kasper CK; McDougal JS; Friedman AE; Hwang DS; Muchmore E; Jordan S; Miller R; Sergis-Davenport E
Transfusion; 1985; 25(6):510-5. PubMed ID: 3934800
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary studies on inactivation of serum HCV].
Liu FH; Tian GS; Fu XX
Zhonghua Yu Fang Yi Xue Za Zhi; 1994 Jan; 28(1):3-5. PubMed ID: 8082457
[TBL] [Abstract][Full Text] [Related]
19. von Willebrand factor characterization of a severe dry-heat treated factor VIII concentrate, AHF (high purity).
Oates A; Polmear E; Herrington R; Farrugia A; Sykes S; Raines G; Aumann H; Street A
Thromb Res; 1992 Feb; 65(3):389-99. PubMed ID: 1631803
[TBL] [Abstract][Full Text] [Related]
20. Storage of thawed cryoprecipitated AHF is better at room temperature than at 1 degree C to 6 degrees C for factor VIII content.
Saxena S; Odono V; Francis R; Shulman IA
Arch Pathol Lab Med; 1991 Apr; 115(4):343-5. PubMed ID: 1901483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
